Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid decline in forced vital capacity: further analyses of the SENSCIS trial

Gläser, S ; Khanna, D ; Maher, T ; Volkmann, E ; Allanore, Y ; Smith, V ; Assassi, S ; Kreuter, M ; Hoffmann-Vold, A ; Kuwana, M ; Stock, C ; Alves, M ; Sambevski, S ; Denton, C

Pneumologie, 2023, Vol.77 (S 01) [Periódico revisado por pares]

Rüdigerstraße 14, 70469 Stuttgart, Germany: Georg Thieme Verlag

Texto completo disponível